Comparison of pharmacokinetic properties, physicochemical stability, and pump compatibility of 3 rapid-acting insulin analogues-aspart, lispro, and glulisine

Endocrine Practice

Volumn 17, Issue 2, 2011, Pages 271-280

  Bode, Bruce W ^a  

^a ATLANTA DIABETES ASSOCIATES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INSULIN ASPART; INSULIN GLULISINE; INSULIN LISPRO;

AMINO ACID SUBSTITUTION; CONTROLLED STUDY; DRUG DECOMPOSITION; DRUG EFFICACY; DRUG POTENCY; DRUG STORAGE; DRUG USE; GLYCEMIC CONTROL; HEART FIBRILLATION; INSULIN INFUSION; INSULIN PUMP; MATERIALS HANDLING; MEDLINE; NONHUMAN; PHYSICAL CHEMISTRY; PRECIPITATION; REVIEW;

DRUG STABILITY; HUMANS; INSULIN;

EID: 79959233609     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP10260.RA     Document Type: Review

References (69)

1. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ. 2002;324:705.
2. Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care. 2002;25:593-598.
3. Karagianni P, Sampanis Ch, Katsoulis Ch, et al. Continuous subcutaneous insulin infusion versus multiple daily injections. Hippokratia. 2009;13:93-96.
4. Monami M, Lamanna C, Marchionni N, Mannucci E. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 1 diabetes: a meta-analysis [published online ahead of print June 6, 2009]. Acta Diabetol. doi:10.1007/s00592-009-0132-5.
5. Pankowska E, Błazik M, Dziechciarz P, Szypowska A, Szajewska H. Continuous subcutaneous insulin infusion vs. multiple daily injections in children with type 1 diabetes: a systematic review and meta-analysis of randomized control trials. Pediatr Diabetes. 2009;10:52-58.
6. Skogsberg L, Fors H, Hanas R, Chaplin JE, Lindman E, Skogsberg J. Improved treatment satisfaction but no difference in metabolic control when using continuous subcutaneous insulin infusion vs. multiple daily injections in children at onset of type 1 diabetes mellitus. Pediatr Diabetes. 2008;9:472-479.
7. Siebenhofer A, Plank J, Berghold A, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev. 2006; (2):CD003287.
8. Heller SR, Colagiuri S, Vaaler S, et al. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with type 1 diabetes. Diabet Med. 2004;21: 769-775. (Pubitemid 38916224)
9. Doyle EA, Weinzimer SA, Steffen AT, Ahern JA, Vincent M, Tamborlane WV. A randomized, prospective trial comparing the effcacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care. 2004;27:1554-1558. (Pubitemid 38857425)
10. Raskin P, Bode BW, Marks JB, et al. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care. 2003;26:2598-2603. (Pubitemid 37052106)
11. Bode BW. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections. Clin Ther. 2007;29(suppl D):S135-S144.
12. Heinemann L, Heise T, Wahl LC, et al. Prandial gly-caemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin. Diabet Med. 1996; 13: 625-629. (Pubitemid 26232502)
13. Rave K, Klein O, Frick AD, Becker RH. Advantage of premeal-injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes. Diabetes Care. 2006;29:1812-1817. (Pubitemid 44156635)
14. Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin aspart: a randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care. 1999;22:801-805. (Pubitemid 29220783)
15. Bode B, Weinstein R, Bell D, et al. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. Diabetes Care. 2002;25:439-444. (Pubitemid 41103333)
16. Brange J, Vølund A. Insulin analogs with improved phar-macokinetic profles. Adv Drug Deliv Rev. 1999;35:307-335. (Pubitemid 29073621)
17. Garnock-Jones KP, Plosker GL. Insulin glulisine: a review of its use in the management of diabetes mellitus. Drugs. 2009;69:1035-1057.
18. Hanaire-Broutin H, Melki V, Bessières-Lacombe S, Tauber JP (Study Group for the Development of Pump Therapy in Diabetes). Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensifed treatment: a randomized study. Diabetes Care. 2000;23:1232-1235.
19. Becker RH, Frick AD, Burger F, Potgieter JH, Scholtz H. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profle in obese non-diabetic subjects. Exp Clin Endocrinol Diabetes. 2005;113:435-443. (Pubitemid 41360749)
20. Helms KL, Kelley KW. Insulin glulisine: an evaluation of its pharmacodynamic properties and clinical application. Ann Pharmacother. 2009;43:658-668.
21. Colquitt J, Royle P, Waugh N. Are analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-analysis. Diabet Med. 2003;20:863-866. (Pubitemid 41701510)
22. Home PD, Barriocanal L, Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. Eur J Clin Pharmacol. 1999;55:199-203. (Pubitemid 29244647)
23. Krones R, Schütte C, Heise T. The rapid-acting properties of insulin aspart are preserved in elderly people with type 2 diabetes. Diabetes Obes Metab. 2009;11:41-44.
24. Renner R, Pfützner A, Trautmann M, Harzer O, Sauter K, Landgraf R (German Humalog-CSII Study Group). Use of insulin lispro in continuous subcutaneous insulin infusion treatment: results of a multicenter trial. Diabetes Care. 1999;22:784-788. (Pubitemid 29220780)
25. DeVries JH, Snoek FJ, Kostense PJ, Masurel N, Heine RJ (Dutch Insulin Pump Study Group). A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control. Diabetes Care. 2002; 25:2074-2080.
26. Lindholm A, Jacobsen LV. Clinical pharmacokinetics and pharmacodynamics of insulin aspart. Clin Pharmacokinet. 2001;40:641-659. (Pubitemid 32954988)
27. Becker RH, Frick AD. Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clin Pharmacokinet. 2008;47:7-20. (Pubitemid 350260885)
28. Becker RH. Insulin glulisine complementing basal insulins: a review of structure and activity. Diabetes Technol Ther. 2007;9:109-121.
29. Bakaysa DL, Radziuk J, Havel HA, et al. Physiochemical basis for the rapid time-action of LysB28ProB29-insulin: dissociation of a protein-ligand complex. Protein Sci. 1996; 5:2521-2531.
30. Brange J, Havelund S, Hommel E, Sørensen E, Kühl C. Neutral insulin solutions physically stabilized by addition of Zn2+. Diabet Med. 1986;3:532-536. (Pubitemid 17187879)
31. Brange J. The new era of biotech insulin analogues. Diabetologia. 1997;40(suppl 2):S48-S53. (Pubitemid 27306922)
32. Brange J, Owens DR, Kang S, Vølund A. Monomeric insulins and their experimental and clinical applications. Diabetes Care. 1990;13:923-954. (Pubitemid 20260734)
33. Overmann H, Heinemann L. Injection-meal interval: recommendations of diabetologists and how patients handle it. Diabetes Res Clin Pract. 1999;43:137-142. (Pubitemid 29155658)
34. Barnett AH, Owens DR. Insulin analogues. Lancet. 1997; 349:47-51. (Pubitemid 27023000)
35. Brange J, Langkjoer L. Insulin structure and stability. In: Wang YJ, Pearlman R, eds. Pharmaceutical Biotechnology. Vol 5. Stability and Characterization of Protein and Peptide Drugs: Case Histories. New York, NY: Plenum Press, 1993: 315-350.
36. Brange J, Ribel U, Hansen JF, et al. Monomeric insulins obtained by protein engineering and their medical implications. Nature. 1988;333:679-682.
37. Brems DN, Alter LA, Beckage MJ, et al. Altering the association properties of insulin by amino acid replacement. Protein Eng. 1992;5:527-533.
38. Brems DN, Brown PL, Bryant C, et al. Improved insulin stability through amino acid substitution. Protein Eng. 1992;5:519-525.
39. Weinzimer SA, Ternand C, Howard C, Chang CT, Becker DJ, Laffel LM (Insulin Aspart Pediatric Pump Study Group). A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes. Diabetes Care. 2008;31:210-215. (Pubitemid 351213321)
40. NovoLog [package insert]. Princeton, NJ: Novo Nordisk A/S; 2010.
41. Humalog [prescribing information]. Indianapolis, IN: Eli Lilly & Company; 2009.
42. Apidra [prescribing information]. Bridgewater NJ: Sanof-Aventis US LLC; 2009.
43. Poulsen C, Langkjaer L, Worsøe C. Precipitation of insulin products used for continuous subcutaneous insulin infusion. Diabetes Technol Ther. 2005;7:142-150. (Pubitemid 40354584)
44. Mecklenburg RS, Guinn TS. Complications of insulin pump therapy: the effect of insulin preparation. Diabetes Care. 1985;8:367-370.
45. Eichner HL, Selam JL, Holleman CB, Worcester BR, Turner DS, Charles MA. Reduction of severe hypoglyce-mic events in type 1 (insulin dependent) diabetic patients using continuous subcutaneous insulin infusion. Diabetes Res. 1988;8:189-193.
46. Brange J, Andersen L, Laursen ED, Meyn G, Rasmussen E. Toward understanding insulin fbrillation. J Pharm Sci. 1997;86:517-525.
47. Arnolds S, Rave K, Hövelmann U, Fischer A, Sert-Langeron C, Heise T. Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers. Exp Clin Endocrinol Diabetes. 2010;118:662-664.
48. Heise T, Nosek L, Spitzer H, et al. Insulin glulisine: a faster onset of action compared with insulin lispro. Diabetes Obes Metab. 2007;9:746-753. (Pubitemid 47261856)
49. Luzio S, Peter R, Dunseath GJ, Mustafa L, Owens DR. A comparison of preprandial insulin glulisine versus insulin lispro in people with type 2 diabetes over a 12-h period. Diabetes Res Clin Pract. 2008;79:269-275.
50. Cobry E, McFann K, Messer L, et al. Timing of meal insulin boluses to achieve optimal postprandial glycemic control in patients with type 1 diabetes. Diabetes Technol Ther. 2010;12:173-177.
51. Jovanovic L, Giammattei J, Acquistapace M, Bornstein K, Sommermann E, Pettitt DJ. Effcacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size. Clin Ther. 2004;26:1492-1497. (Pubitemid 39582716)
52. Hoogma RP, Schumicki D. Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes. Horm Metab Res. 2006;38:429-433. (Pubitemid 44047966)
53. Dreyer M, Prager R, Robinson A, et al. Effcacy and safety of insulin glulisine in patients with type 1 diabetes. Horm Metab Res. 2005;37:702-707. (Pubitemid 41810494)
54. Plank J, Wutte A, Brunner G, et al. A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. Diabetes Care. 2002;25:2053-2057. (Pubitemid 41071068)
55. Bartolo PD, Pellicano F, Scaramuzza A, et al. Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes. Diabetes Technol Ther. 2008;10:495-498.
56. Hedman CA, Lindström T, Arnqvist HJ. Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profles after subcutaneous injection in type 1 diabetes. Diabetes Care. 2001;24:1120-1121.
57. Selam JL, Zirinis P, Mellet M, Mirouze J. Stable insulin for implantable delivery systems: in vitro studies with different containers and solvents. Diabetes Care. 1987;10: 343-347. (Pubitemid 17083578)
58. Brange J, Havelund S. Insulin pumps and insulin quality\requirements and problems. Acta Med Scand Suppl. 1983;671:135-138.
59. Poulsen C, Langkjaer L, Worsøe C. Precipitation of insulin aspart and insulin glulisine products used for continuous subcutaneous insulin infusion. Diabetes Technol Ther. 2007;9:26-35.
60. Senstius J, Harboe E, Westermann H. In vitro stability of insulin aspart in simulated continuous subcutaneous insulin infusion using a MiniMed 508 insulin pump. Diabetes Technol Ther. 2007;9:75-79.
61. Senstius J, Poulsen C, Hvass A. Comparison of in vitro stability for insulin aspart and glulisine during simulated use in insulin pumps. Diabetes Technol Ther. 2007;9: 517-521. (Pubitemid 350158794)
62. DeFelippis MR, Bell MA, Heyob JA, Storms SM. In vitro stability of insulin lispro in continuous subcutaneous insulin infusion. Diabetes Technol Ther. 2006;8:358-368. (Pubitemid 46100529)
63. Kerr D, Morton J, Whately-Smith C, Everett J, Begley JP. Laboratory-based non-clinical comparison of occlusion rates using three rapid-acting insulin analogs in continuous subcutaneous insulin infusion catheters using low fow rates. J Diabetes Sci Technol. 2008;2:450-455.
64. Bode BW, Strange P. Effcacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes. Diabetes Care. 2001;24:69-72. (Pubitemid 32104222)
65. Wolpert HA, Faradji RN, Bonner-Weir S, Lipes MA. Metabolic decompensation in pump users due to lispro insulin precipitation. BMJ. 2002;324:1253. (Pubitemid 34553564)
66. Siegmund T, von Amelunxen S, Kaiser M, Oeffner A, Schumm-Draeger PM. Pump compatibility of insulin aspart compared to insulin lispro with respect to catheter complications and dermal/subcutaneous irritations in type 1 diabetes patients undergoing insulin pump therapy (CSII) [abstract]. Diabetes. 2005;54(suppl 1):A105.
67. Lougheed WD, Zinman B, Strack TR, et al. Stability of insulin lispro in insulin infusion systems. Diabetes Care. 1997;20:1061-1065. (Pubitemid 27274263)
68. Wright AW, Little JA. Cannula occlusion with use of insulin lispro and insulin infusion system. Diabetes Care. 1998; 21:874-875. (Pubitemid 28487094)
69. Wittlin SD, Marcus AO, Weng CS, Howard CP, Schorr AB (CONTROL Study Group). Evaluation of treatment satisfaction associated with the use of insulin aspart in continuous subcutaneous insulin infusion. Diabetes Technol Ther. 2008;10:1-10